Innocan Pharma Corp C.INNO

Alternate Symbol(s): INNPF

Healthcare

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

CSE:INNO - Post by User

Innocan Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Aug 25, 2023 6:59pm

241 Views

Post# 35606227

Innocan Pharma Reports Q2 2023 Results

US$3.121M Revenues for Q2, 2023 compared to US$415,000 for Q2 2022, representing an increase of 652%
US$2.656M Gross Profit for Q2, 2023 compared to USD 214,000 for Q2 2022, representing an increase of approximately 1,141%

HERZLIYA, Israel and CALGARY, AB, Aug. 25, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and six months period ended June 30, 2023.

Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022 (newswire.ca)